Minerva Neurosciences Net Income Over Time
| NERV Stock | USD 6.27 0.02 0.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Minerva Neurosciences Performance and Minerva Neurosciences Correlation. What growth prospects exist in Biotechnology sector? Can Minerva capture new markets? Factors like these will boost the valuation of Minerva Neurosciences. Anticipated expansion of Minerva directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Minerva Neurosciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Understanding Minerva Neurosciences requires distinguishing between market price and book value, where the latter reflects Minerva's accounting equity. The concept of intrinsic value - what Minerva Neurosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Market sentiment, economic cycles, and investor behavior can push Minerva Neurosciences' price substantially above or below its fundamental value.
It's important to distinguish between Minerva Neurosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Minerva Neurosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Minerva Neurosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Minerva Neurosciences and related stocks such as Klotho Neurosciences, Sonnet Biotherapeutics, and Neurosense Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KLTO | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (1.1 M) | (598.6 K) | (707.5 K) | (6.2 M) | (5.5 M) | (5.3 M) |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| XCUR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (16.9 M) | (11 M) | (22.4 M) | (26.3 M) | (24.7 M) | (64.1 M) | (2.6 M) | (16.9 M) | (9.7 M) | (8.7 M) | (9.2 M) |
| NRXS | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3 M) | (4.8 M) | (14.6 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| CLGN | (4.5 M) | (4.5 M) | (4.5 M) | (4.6 M) | (3.6 M) | (4.8 M) | (7.3 M) | (5.8 M) | (6.2 M) | (11.2 M) | (5.8 M) | 237 K | (16.9 M) | (7 M) | (16.6 M) | (14.9 M) | (14.2 M) |
| TAOX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (5.6 M) | (6 M) | (12.8 M) | (11.5 M) | (12.1 M) |
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| CVKD | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (8.4 M) | (10.7 M) | (9.6 M) | (10.1 M) |
| ENLV | (229 K) | (229 K) | (229 K) | (1.1 M) | (7 M) | (15.4 M) | (16 M) | (5.9 M) | (4.9 M) | (9.4 M) | (11.8 M) | (14.5 M) | (31.1 M) | (29.1 M) | (15 M) | (13.5 M) | (14.2 M) |
Minerva Neurosciences and related stocks such as Klotho Neurosciences, Sonnet Biotherapeutics, and Neurosense Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Minerva Neurosciences financial statement analysis. It represents the amount of money remaining after all of Minerva Neurosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Minerva Neurosciences | NERV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1500 District Avenue, |
| Exchange | NASDAQ Exchange |
USD 6.27
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.